General Availability of the Fosfor Decision Cloud Debuts, Enabling Amplified Business Outcomes on the Snowflake AI Data Cloud

4.9.2024 15:00:00 CEST | Business Wire | Press release

Fosfor today announced the general availability (GA) of its Fosfor Decision Cloud, a Snowflake-integrated platform that unifies the components of the modern data stack into a modern decision stack, built to simplify AI and amplify business outcomes. This robust and comprehensive data-to-decisions platform hits the market with Snowflake Partner Connect integration, Snowflake Technology Ready validation, and AI-enabling integrations.

The GA release builds on the success and adoption of the private preview version rolled out in February, adding:

Snowflake Partner Connect integration, enabling users to easily, quickly, and securely enroll in a free Fosfor trial directly from their Snowflake accounts, making Fosfor’s business-outcome-enhancing capabilities readily available to all Snowflake customers.
Snowflake Technology Ready validation, giving users the confidence that comes with a third-party technical validation to confirm Fosfor’s Snowflake integrations are optimized with an emphasis on functional and performance best practices.
Integration with Snowflake’s latest AI capabilities, allowing users to streamline and simplify their AI journey by running AI directly where their data is already secure and governed. This is possible by leveraging Snowpark Container Services for ML lifecycle support and Snowflake Cortex AI for creating GenAI apps.

The GA release strengthens Fosfor’s commitment to Snowflake as its data and AI platform partner.

“General availability of the Fosfor Decision Cloud represents the culmination of our multi-year journey to simplify AI with the most comprehensive Decision Intelligence platform,” said Debasis Satpathy, Chief Business Officer, Fosfor. “This release delivers capabilities that expand the FDC’s suitability for a growing list of industries, and further strengthens our partnership with Snowflake, all in a stable, robust, enterprise-grade product.”

“Companies in every industry are looking for ways to more quickly realize return on their data and technology investments,” said Tarik Dwiek, Head of Technology Alliances, Snowflake. “The tightly integrated combination of the Fosfor Decision Cloud and the Snowflake AI Data Cloud provides the acceleration sought by customers looking to extract valuable insights from their data.”

The GA release of the Fosfor Decision Cloud is available now. Learn more at www.fosfor.com.

About Fosfor

The Fosfor Decision Cloud is a connected fabric that unifies and amplifies the value promised by the modern data ecosystem, which is made up of infrastructure, data, and application clouds. Fosfor enables organizations to effectively curate data, generate impactful insights, and formulate effective decisions to deliver the long-sought promise of data and AI: optimal business outcomes. Fosfor is part of LTIMindtree, a global technology consulting and digital solutions company. For more information, visit www.fosfor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240903753120/en/

Contacts

Gitanjali Sreepal, Global Media Relations, Gitanjali.sreepal@ltimindtree.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom